Release Date: October 31, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: In the XPro Phase II Alzheimer's trial, how selective have you been with patient enrollment, and will this be a challenge for a potential Phase III trial? A: Raymond Tesi, CEO, explained that they focus on patients with inflammation driving their Alzheimer's Disease, which is about 50% of patients. This strategy helps de-risk the clinical trial. The regulatory aspect will be discussed with the FDA after Phase II, but they are confident in managing it. CJ Barnum, VP of Drug Development, added that the selectivity is more about ensuring similar pathology in early phase studies.
Q: Could the timing of the Alzheimer's trial data readout be pushed to later in Q2 due to patients still in screening? A: Raymond Tesi confirmed that while there are a few extra patients in screening, the drop-dead date for enrollment is about 10 days away. They are comfortable with the Q2 timeline for data release, provided the clinical operations team ensures clean and correct data.
Q: How does the recent acquisition of Aliada by AbbVie impact your thinking about potential M&A in the Alzheimer's space? A: Raymond Tesi stated that most M&A activity is in the amyloid or tau path, and they believe once they show that targeting glial activation makes a difference, conversations will start. Currently, there are no deep-seated business development discussions, as it's all about data.
Q: Regarding the depression study, are the inflammatory biomarkers the same as those in Alzheimer's Disease? A: CJ Barnum explained that they are enriching for patients with inflammation using blood C-reactive protein and a behavioral biomarker of anhedonia. These biomarkers are consistent across their programs, with about 40% to 50% of patients meeting the criteria.
Q: What do you need to see in the INKmune trial to justify continued investment, specifically regarding tumor impact? A: Mark Lowdell, CSO, stated that they are looking for changes in immune response against tumors. They have some evidence of tumor shrinkage, and any clinical outcome convincing the chief investigator of a response would justify further investment. Raymond Tesi added that a therapy prolonging life with good quality is important, especially for older patients who can't tolerate traditional regimens.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.